Basic Information
APEXXNAR SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML
INJECTION, SUSPENSION
Regulatory Information
SIN16648P
November 30, 2022
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
May 30, 2025
XJ07AL02
Company Information
Active Ingredients
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: Approx. 51 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 4.4 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Strength: 2.2 μg/0.5ml
Detailed Information
Contraindications
**4.3. Contraindications** Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_, or to diphtheria toxoid.
Indication Information
**4.1. Therapeutic indications** Active immunisation for the prevention of invasive disease and pneumonia caused by _Streptococcus pneumoniae_ in individuals 18 years of age and older. See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Apexxnar should be used in accordance with official recommendations.